Dear ,

In the current issue of the OncoWuXi Newsletter, we share with you the update on our service and newly established capabilities.

OncoWuXi Newsletter will continue to keep you up to date with our recent progress in cancer research. As a part of the WuXi AppTec Research Service Division (RSD), our top-notch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases, and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.
WuXi AppTec Immune-Avatar Humanized Models

(1)  hPBMC humanized models
  • T cell focused studies: quick and flexible
  • 3 systems for different study purposes
  • Allow for studies on 1500+ WuXi PDX/CDX models

(2)  hHSC humanized models
  • Multi-lineage reconstitution
  • Long-term and stable model of human immune system engraftment
  • Allow for studies on 1500+ WuXi PDX/CDX models

Translational Oncology
Palbociclib-induced Resistance Model of MCF-7

(1)  In vivo drug-induced resistance model by long-term administration of Palbociclib on MCF-7 tumor-bearing mice

(2)  In vitro drug-induced resistance model by chronic exposure to increased concentrations of Palbociclib on MCF-7 cells

Targeted Oncology
WuXi AppTec FLT3-related In Vivo Models

(1)    MV4-11 leukemia CDX model, tested with Sunitinib, Quizartinib, TAK-659, Ponatinib, and Sorafenib

(2)    Ba/F3 cell lines, tested with Ponatinib, Sunitinib, Sorafenib, and Quizartinib in vitro or in vivo:
  • Ba/F3-FLT3-ITD
  • Ba/F3-FLT3-ITD-F691L
  • Ba/F3-FLT3-ITD-D835Y

(3)    Newly established MV4-11 cell lines overexpressing:
  • FLT3-ITD-F691L
  • FLT3-ITD-D835Y

WuXi AppTec RET-related In Vivo Models

(1)  TT thyroid and LC-2/ad lung cancer CDX models harboring RET alterations

(2)  Ba/F3 cell lines, tested with Cabozantinib, Vandetanib, Lenvatinib, Sunitinib, Regorafenib, Pralsetinib, Ponatinib, Sorafenib, and LOXO-292 in vitro or in vivo:
  • Ba/F3-KIF5B-RET
  • Ba/F3-KIF5B-RET-V804L
  • Ba/F3-KIF5B-RET-V804M
  • Ba/F3-CCDC6-RET
  • Ba/F3-CCDC6-RET-V804M
  • Ba/F3-CCDC6-RET-V804L

(3)  Newly established Ba/F3 cell lines:
  • Ba/F3-KIF5B-RET-G810S
  • Ba/F3-KIF5B-RET-G810R

We sincerely appreciate your interest, time and support, and would like to hear your feedback so that we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns. 
Best regards,
WuXi AppTec OncoWuXi Team